New UK Biosimilars Pathway Suffers Setback
MHRA Consultation Review Delayed Due To ‘Intense COVID-19 Activities’
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.
